BIOMAT Database Logo BIOMAT Database Logo

Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children. 1989

A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Major advances have been made in elucidating the etiologic agents of severe infantile diarrhea, and it is clear that rotaviruses are the single most important etiologic agents. Progress in the development of rotavirus vaccine candidates has also moved swiftly with the "Jennerian" approach, in which a related live, attenuated rotavirus strain from a nonhuman host is used as the immunizing antigen. If this strategy is not effective against all rotavirus serotypes, reassortant rotaviruses hold great promise for the development of a multivalent vaccine. Field trials with the "Jennerian" approach vaccines are under way, and phase 1 trials with the reassortants have been initiated.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D003968 Diarrhea, Infantile DIARRHEA occurring in infants from newborn to 24-months old. Infantile Diarrhea,Diarrheas, Infantile,Infantile Diarrheas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012400 Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice. Infection, Rotavirus,Infections, Rotavirus,Rotavirus Infection
D012401 Rotavirus A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized. Neonatal Calf Diarrhea Virus,Rotaviruses
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Rotavirus vaccine development for the prevention of severe diarrhea in infants and young children.
July 1994, Trends in microbiology,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.
September 1996, The Journal of infectious diseases,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
[Rotavirus diarrhea in young infants].
December 1979, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis.
October 2004, The Pediatric infectious disease journal,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal.
January 2001, Novartis Foundation symposium,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Rotavirus vaccine and severe diarrhea in African infants.
April 2010, The New England journal of medicine,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Rotavirus vaccine and severe diarrhea in African infants.
April 2010, The New England journal of medicine,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.
September 1988, The Journal of infectious diseases,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children.
May 1986, The Journal of infectious diseases,
A Z Kapikian, and J Flores, and Y Hoshino, and K Midthun, and M Gorziglia, and K Y Green, and R M Chanock, and L Potash, and S D Sears, and M L Clements
Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case-control study.
May 2014, Vaccine,
Copied contents to your clipboard!